Cargando…

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease

INTRODUCTION: As the role of biomarkers is increasing in Alzheimer's disease (AD) clinical trials, it is critical to use a comprehensive temporal biomarker profile that reflects both baseline and longitudinal assessments to establish a more precise association between the change in biomarkers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guoqiao, Xiong, Chengjie, McDade, Eric M., Hassenstab, Jason, Aschenbrenner, Andrew J., Fagan, Anne M., Benzinger, Tammie L.S., Gordon, Brian A., Morris, John C., Li, Yan, Bateman, Randall J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288312/
https://www.ncbi.nlm.nih.gov/pubmed/30569014
http://dx.doi.org/10.1016/j.trci.2018.10.009
_version_ 1783379774342692864
author Wang, Guoqiao
Xiong, Chengjie
McDade, Eric M.
Hassenstab, Jason
Aschenbrenner, Andrew J.
Fagan, Anne M.
Benzinger, Tammie L.S.
Gordon, Brian A.
Morris, John C.
Li, Yan
Bateman, Randall J.
author_facet Wang, Guoqiao
Xiong, Chengjie
McDade, Eric M.
Hassenstab, Jason
Aschenbrenner, Andrew J.
Fagan, Anne M.
Benzinger, Tammie L.S.
Gordon, Brian A.
Morris, John C.
Li, Yan
Bateman, Randall J.
author_sort Wang, Guoqiao
collection PubMed
description INTRODUCTION: As the role of biomarkers is increasing in Alzheimer's disease (AD) clinical trials, it is critical to use a comprehensive temporal biomarker profile that reflects both baseline and longitudinal assessments to establish a more precise association between the change in biomarkers and change in cognition. Because age of onset of dementia symptoms is highly predictable, and there are relatively few age-related comorbidities, the Dominantly Inherited Alzheimer Network autosomal dominant AD population affords a unique opportunity to investigate these relationships in a well-characterized population. METHODS: A novel joint statistical model was used to simultaneously evaluate how a comprehensive AD biomarker profile predicts change in cognition using amyloid positron emission tomography (PET), CSF Aβ(42), CSF total tau and Ptau(181), cortical metabolism using [F-18] fluorodeoxyglucose–PET, and hippocampal volume from participants enrolled in the Dominantly Inherited Alzheimer Network (n = 262) with mean (SD) duration of follow-up of 2.7 (1.2) years. RESULTS: Baseline amyloid PET levels and CSF biomarkers were associated with change in cognition in contrast to the rate of change of brain metabolism and hippocampal volume, which predicted change in cognition. CONCLUSIONS: This study suggests that the baseline value of amyloid PET and CSF Aβ(42) measures may be useful for screening participants for AD trials; however, brain hippocampus atrophy and hypometabolism are only useful as repeated longitudinal assessments for tracking cognition and disease progression. This suggests that measures of amyloid plaques predict future cognitive decline, but only longitudinal measures of neurodegeneration correlate with cognitive decline. The novel statistical model used in this study can be easily applied to any pair of outcomes and has potential to be widely used by the AD research community.
format Online
Article
Text
id pubmed-6288312
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62883122018-12-19 Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease Wang, Guoqiao Xiong, Chengjie McDade, Eric M. Hassenstab, Jason Aschenbrenner, Andrew J. Fagan, Anne M. Benzinger, Tammie L.S. Gordon, Brian A. Morris, John C. Li, Yan Bateman, Randall J. Alzheimers Dement (N Y) Featured Article INTRODUCTION: As the role of biomarkers is increasing in Alzheimer's disease (AD) clinical trials, it is critical to use a comprehensive temporal biomarker profile that reflects both baseline and longitudinal assessments to establish a more precise association between the change in biomarkers and change in cognition. Because age of onset of dementia symptoms is highly predictable, and there are relatively few age-related comorbidities, the Dominantly Inherited Alzheimer Network autosomal dominant AD population affords a unique opportunity to investigate these relationships in a well-characterized population. METHODS: A novel joint statistical model was used to simultaneously evaluate how a comprehensive AD biomarker profile predicts change in cognition using amyloid positron emission tomography (PET), CSF Aβ(42), CSF total tau and Ptau(181), cortical metabolism using [F-18] fluorodeoxyglucose–PET, and hippocampal volume from participants enrolled in the Dominantly Inherited Alzheimer Network (n = 262) with mean (SD) duration of follow-up of 2.7 (1.2) years. RESULTS: Baseline amyloid PET levels and CSF biomarkers were associated with change in cognition in contrast to the rate of change of brain metabolism and hippocampal volume, which predicted change in cognition. CONCLUSIONS: This study suggests that the baseline value of amyloid PET and CSF Aβ(42) measures may be useful for screening participants for AD trials; however, brain hippocampus atrophy and hypometabolism are only useful as repeated longitudinal assessments for tracking cognition and disease progression. This suggests that measures of amyloid plaques predict future cognitive decline, but only longitudinal measures of neurodegeneration correlate with cognitive decline. The novel statistical model used in this study can be easily applied to any pair of outcomes and has potential to be widely used by the AD research community. Elsevier 2018-12-07 /pmc/articles/PMC6288312/ /pubmed/30569014 http://dx.doi.org/10.1016/j.trci.2018.10.009 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Featured Article
Wang, Guoqiao
Xiong, Chengjie
McDade, Eric M.
Hassenstab, Jason
Aschenbrenner, Andrew J.
Fagan, Anne M.
Benzinger, Tammie L.S.
Gordon, Brian A.
Morris, John C.
Li, Yan
Bateman, Randall J.
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
title Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
title_full Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
title_fullStr Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
title_full_unstemmed Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
title_short Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
title_sort simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited alzheimer's disease
topic Featured Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288312/
https://www.ncbi.nlm.nih.gov/pubmed/30569014
http://dx.doi.org/10.1016/j.trci.2018.10.009
work_keys_str_mv AT wangguoqiao simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT xiongchengjie simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT mcdadeericm simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT hassenstabjason simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT aschenbrennerandrewj simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT faganannem simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT benzingertammiels simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT gordonbriana simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT morrisjohnc simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT liyan simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT batemanrandallj simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease
AT simultaneouslyevaluatingtheeffectofbaselinelevelsandlongitudinalchangesindiseasebiomarkersoncognitionindominantlyinheritedalzheimersdisease